Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [31] Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
    Rao, Ding-Yu
    Huang, De-Fa
    Si, Mao-Yan
    Lu, Hua
    Tang, Zhi-Xian
    Zhang, Zu-Xiong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] A prospective observational multicenter cfDNA study in EGFR-mutated non-small cell lung cancer treated with osimertinib
    Osuga, Mitsuo
    Tamiya, Akihiro
    Mizumori, Yasuyuki
    Isa, Shunichi
    Fujita, Yuka
    Kozuki, Toshiyuki
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Tamura, Atsuhisa
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER SCIENCE, 2024, 115 : 845 - 845
  • [33] Adjuvant chemotherapy for early-stage non-small cell lung cancer
    Visbal, AL
    Leighl, NB
    Feld, R
    Shepherd, FA
    CHEST, 2005, 128 (04) : 2933 - 2943
  • [34] Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer
    Serke, Monika
    CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 : 135 - 144
  • [35] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S497 - S497
  • [36] Adjuvant chemotherapy in early-stage non-small cell lung cancer
    Dômont, J
    Soria, JC
    Le Chevalier, T
    SEMINARS IN ONCOLOGY, 2005, 32 (03) : 279 - 283
  • [37] Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Urisman, Anatoly
    Gubens, Matthew A.
    Mulvey, Claire
    Allen, Greg M.
    Rotow, Julia K.
    Kerr, Daniel Lucas
    Chakrabarti, Turja
    Bacaltos, Bianca
    Gee, Megan
    Jones, Kirk
    Aisner, Dara L.
    Patil, Tejas
    Schenk, Erin Lynn
    Bivona, Trever G.
    Riess, Jonathan W.
    Coleman, Melissa
    Kratz, Johannes Ruediger
    Jablons, David
    Blakely, Collin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Huu-Vinh Vu
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    FUTURE ONCOLOGY, 2021, 17 (35) : 4827 - 4835
  • [39] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [40] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
    Bertoli, Elisa
    De Carlo, Elisa
    Del Conte, Alessandro
    Stanzione, Brigida
    Revelant, Alberto
    Fassetta, Kelly
    Spina, Michele
    Bearz, Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
12345